Skip to content

Study · Other design · 2025

2 results

A Combined Modeling Approach to Predict the Effect of Gastric Emptying Delay on the Pharmacokinetics of Small Molecules.

Posada MM, Schneck KB, Morse BL, Rougee LRA, Tham LS, Rehmel JF, Thompson B, Stamatis SD, Hall SD, Dickinson GL

CPT: pharmacometrics & systems pharmacology21 Aug 2025Cited by 2 (Europe PMC)

PMID40842022 (opens in a new tab)PMCIDPMC12706417 (opens in a new tab)DOI10.1002/psp4.70101 (opens in a new tab)PepBankPUB-40842022
Read at sourcePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study2

1 result from studies that gave the peptide. 1 result from people.

  1. 01HumanOther designPharmacokinetics

    In clinical studies, dulaglutide had no clinically relevant effect on small-molecule pharmacokinetics at 1.5 mg.

    In plain wordsIn clinical studies, dulaglutide had no clinically relevant effect on small-molecule drug levels at 1.5 mg.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    Direction not reportedSmall-molecule pharmacokinetics
    Study

    n: not reported in source

    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    1.5 mgAs given in this study (human).

    Source sentences

    Summary
    The clinical studies demonstrated that the 1.5 mg dulaglutide dose has no clinically relevant effect on the pharmacokinetics of small molecules, and the modeling led to a similar conclusion at 4.5 mg dulaglutide.
    2 context sentences
    Summary · context
    In clinical studies, the gastric emptying delay (GED) was evaluated in healthy participants and patients with T2DM at various dose levels of dulaglutide.
    Summary · context
    This research investigates the effect of dulaglutide on gastric emptying and its impact on the pharmacokinetics (PK) of orally administered molecules utilizing a combination of population pharmacokinetic (PopPK) and physiologically based pharmacokinetic (PBPK) modeling approaches.

Studies that did not test the peptide alone1

In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Dulaglutide (Trulicity).

  1. 02Computer modelNot a test of Dulaglutide (Trulicity) aloneIn silicoPharmacokinetics

    In pharmacokinetic models, dulaglutide-induced gastric emptying delay had no clinically relevant predicted effect on small-molecule pharmacokinetics at 4.5 mg.

    In plain wordsIn computer models, dulaglutide had no clinically relevant predicted effect on small-molecule drug levels at 4.5 mg.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    Not applicablePredicted small-molecule pharmacokinetics
    Study

    n: not reported in source

    Outcome group
    Pharmacokinetics · Pharmacology

    Source sentences

    Summary
    The clinical studies demonstrated that the 1.5 mg dulaglutide dose has no clinically relevant effect on the pharmacokinetics of small molecules, and the modeling led to a similar conclusion at 4.5 mg dulaglutide.
    1 context sentence
    Summary · context
    This research investigates the effect of dulaglutide on gastric emptying and its impact on the pharmacokinetics (PK) of orally administered molecules utilizing a combination of population pharmacokinetic (PopPK) and physiologically based pharmacokinetic (PBPK) modeling approaches.

    In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:25 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.